Form 4: UNITED THERAPEUTICS CEO Sells Shares
Insider Transaction (Form 4)
Martine A Rothblatt, Chairperson & CEO and a Director of UNITED THERAPEUTICS Corp, sold 9,500 shares of common stock on September 10, 2026.
Summary
- Option exercise/conversion: acquired 9,500 Common Stock at $117.76 ($1,118,720) on September 10, 2026; holds 333,943 after (Indirect).
- Open-market sale: disposed of 120 Common Stock at $498.44 ($59,813) on September 10, 2026; holds 333,823 after (Indirect).
- Open-market sale: disposed of 1,788 Common Stock at $499.75 ($893,548) on September 10, 2026; holds 332,035 after (Indirect).
- Open-market sale: disposed of 1,372 Common Stock at $500.58 ($686,797) on September 10, 2026; holds 330,663 after (Indirect).
- Open-market sale: disposed of 2,244 Common Stock at $501.88 ($1,126,209) on September 10, 2026; holds 328,419 after (Indirect).
- Open-market sale: disposed of 1,536 Common Stock at $502.80 ($772,300) on September 10, 2026; holds 326,883 after (Indirect).
- Open-market sale: disposed of 578 Common Stock at $503.76 ($291,174) on September 10, 2026; holds 326,305 after (Indirect).
- Open-market sale: disposed of 702 Common Stock at $505.03 ($354,533) on September 10, 2026; holds 325,603 after (Indirect).
- Open-market sale: disposed of 600 Common Stock at $505.94 ($303,564) on September 10, 2026; holds 325,003 after (Indirect).
- Open-market sale: disposed of 280 Common Stock at $506.76 ($141,893) on September 10, 2026; holds 324,723 after (Indirect).
- Open-market sale: disposed of 280 Common Stock at $508.80 ($142,465) on September 10, 2026; holds 324,443 after (Indirect).
- Option exercise/conversion: disposed of 9,500 Stock Option on September 10, 2026; holds 461,410 after (Indirect).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $4,772,295 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Martine A Rothblatt — Director, Officer (Chairperson & CEO)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-10 | Option exercise/conversion | Common Stock | 9,500 | $118 | $1.1M | 333,943 |
| 2026-09-10 | Open-market sale | Common Stock | 120 | $498 | $59.8K | 333,823 |
| 2026-09-10 | Open-market sale | Common Stock | 1,788 | $500 | $893.5K | 332,035 |
| 2026-09-10 | Open-market sale | Common Stock | 1,372 | $501 | $686.8K | 330,663 |
| 2026-09-10 | Open-market sale | Common Stock | 2,244 | $502 | $1.1M | 328,419 |
| 2026-09-10 | Open-market sale | Common Stock | 1,536 | $503 | $772.3K | 326,883 |
| 2026-09-10 | Open-market sale | Common Stock | 578 | $504 | $291.2K | 326,305 |
| 2026-09-10 | Open-market sale | Common Stock | 702 | $505 | $354.5K | 325,603 |
| 2026-09-10 | Open-market sale | Common Stock | 600 | $506 | $303.6K | 325,003 |
| 2026-09-10 | Open-market sale | Common Stock | 280 | $507 | $141.9K | 324,723 |
| 2026-09-10 | Open-market sale | Common Stock | 280 | $509 | $142.5K | 324,443 |
| 2026-09-10 | Option exercise/conversion | Stock Option | 9,500 | — | — | 461,410 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-10 | Option exercise/conversion (9,500 shares) |
| 2026-09-10 | Open-market sale (120 shares) |
| 2026-09-10 | Open-market sale (1,788 shares) |
| 2026-09-10 | Open-market sale (1,372 shares) |
| 2026-09-10 | Open-market sale (2,244 shares) |
| 2026-09-10 | Open-market sale (1,536 shares) |
| 2026-09-10 | Open-market sale (578 shares) |
| 2026-09-10 | Open-market sale (702 shares) |
| 2026-09-10 | Open-market sale (600 shares) |
| 2026-09-10 | Open-market sale (280 shares) |
| 2026-09-10 | Open-market sale (280 shares) |
| 2026-09-10 | Option exercise/conversion (9,500 shares) |
Keywords
insider transaction, Form 4, UTHR, UNITED THERAPEUTICS Corp, bearish, Martine A Rothblatt
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.